JP2018519327A5 - - Google Patents

Download PDF

Info

Publication number
JP2018519327A5
JP2018519327A5 JP2017568200A JP2017568200A JP2018519327A5 JP 2018519327 A5 JP2018519327 A5 JP 2018519327A5 JP 2017568200 A JP2017568200 A JP 2017568200A JP 2017568200 A JP2017568200 A JP 2017568200A JP 2018519327 A5 JP2018519327 A5 JP 2018519327A5
Authority
JP
Japan
Prior art keywords
cancer
combination
combination according
administered
immunotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017568200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040080 external-priority patent/WO2017004192A1/en
Publication of JP2018519327A publication Critical patent/JP2018519327A/ja
Publication of JP2018519327A5 publication Critical patent/JP2018519327A5/ja
Priority to JP2021143803A priority Critical patent/JP2021183650A/ja
Priority to JP2024100476A priority patent/JP2024111247A/ja
Withdrawn legal-status Critical Current

Links

JP2017568200A 2015-06-29 2016-06-29 治療用組成物、組合せ物および使用の方法 Withdrawn JP2018519327A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021143803A JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法
JP2024100476A JP2024111247A (ja) 2015-06-29 2024-06-21 治療用組成物、組合せ物および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186197P 2015-06-29 2015-06-29
US62/186,197 2015-06-29
PCT/US2016/040080 WO2017004192A1 (en) 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021143803A Division JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法

Publications (2)

Publication Number Publication Date
JP2018519327A JP2018519327A (ja) 2018-07-19
JP2018519327A5 true JP2018519327A5 (enExample) 2019-07-11

Family

ID=57609144

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017568200A Withdrawn JP2018519327A (ja) 2015-06-29 2016-06-29 治療用組成物、組合せ物および使用の方法
JP2021143803A Withdrawn JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法
JP2024100476A Pending JP2024111247A (ja) 2015-06-29 2024-06-21 治療用組成物、組合せ物および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021143803A Withdrawn JP2021183650A (ja) 2015-06-29 2021-09-03 治療用組成物、組合せ物および使用の方法
JP2024100476A Pending JP2024111247A (ja) 2015-06-29 2024-06-21 治療用組成物、組合せ物および使用の方法

Country Status (13)

Country Link
US (3) US10532056B2 (enExample)
EP (2) EP4488265A3 (enExample)
JP (3) JP2018519327A (enExample)
KR (1) KR102783581B1 (enExample)
CN (2) CN114209841A (enExample)
AU (3) AU2016286091B2 (enExample)
CA (2) CA3244408A1 (enExample)
EA (1) EA201890161A1 (enExample)
ES (1) ES2987376T3 (enExample)
IL (2) IL256652B2 (enExample)
MX (2) MX389683B (enExample)
WO (1) WO2017004192A1 (enExample)
ZA (1) ZA201800572B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101974254B1 (ko) 2013-07-18 2019-04-30 다이호야쿠힌고교 가부시키가이샤 Fgfr 저해제의 간헐 투여용 항종양제
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
KR20240159639A (ko) * 2014-01-09 2024-11-05 베라스템, 인코포레이티드 비정상적 세포 성장의 치료를 위한 조성물 및 방법
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
JP6823067B2 (ja) 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
MX2019009386A (es) 2017-02-07 2019-11-05 Univ Saitama Medical Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer.
ES2983582T3 (es) 2017-04-07 2024-10-23 Tambo Inc Composiciones bioortogonales
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
US11452764B2 (en) * 2017-07-21 2022-09-27 University Of North Dakota Inhibiting FAK-AKT interaction to inhibit metastasis
CN112218658A (zh) * 2018-03-12 2021-01-12 国家健康科学研究所 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
EP4470621A3 (en) 2018-03-19 2025-05-07 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
AU2019414550B2 (en) * 2018-12-27 2022-09-22 Hinova Pharmaceuticals Inc. FAK inhibitor and drug combination thereof
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
JP7606225B2 (ja) 2019-02-20 2024-12-25 学校法人 埼玉医科大学 放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー
EP3932427A4 (en) * 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY USING A 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND AND PEMBROLIZUMAB
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
TWI757716B (zh) * 2019-04-15 2022-03-11 禾榮科技股份有限公司 微創型中子束產生裝置及微創型中子捕獲治療系統
WO2020230588A1 (ja) 2019-05-10 2020-11-19 富士フイルム株式会社 光照射装置およびセンサー
CN110201171A (zh) * 2019-06-18 2019-09-06 北京大学 Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用
US20230139944A1 (en) * 2019-06-21 2023-05-04 Board Of Regents, The University Of Texas System Targeting alpha3beta1 integrin for treatment of cancer and other diseases
JP7622031B2 (ja) * 2019-07-05 2025-01-27 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
CN114667144A (zh) * 2019-11-18 2022-06-24 应世生物科技(南京)有限公司 Fak抑制剂在制备用于治疗nras突变的肿瘤的药物中的用途
CA3159860C (en) * 2019-11-28 2025-05-20 Inxmed (Nanjing) Co., Ltd. USE OF BI853520 IN CANCER TREATMENT
MX2022009347A (es) * 2020-01-31 2022-12-15 Verastem Inc Terapia de combinacion para el tratamiento del crecimiento celular anormal.
AU2021215747A1 (en) 2020-02-05 2022-08-18 Inxmed (Nanjing) Co., Ltd. Combination of BI853520 with chemotherapeutic drugs
WO2021161994A1 (ja) 2020-02-14 2021-08-19 富士フイルム株式会社 光結合システムおよび光通信デバイス
CA3189383A1 (en) * 2020-07-13 2022-01-20 Verastem, Inc. Combination therapy for treating abnormal cell growth
PE20231303A1 (es) * 2020-08-03 2023-08-24 Inxmed Nanjing Co Ltd Forma solida de compuesto
US12589162B2 (en) 2020-08-07 2026-03-31 Tambo, Inc. Trans-cyclooctene prodrug of monomethyl auristatin E
WO2022125652A1 (en) * 2020-12-08 2022-06-16 Cornell University Methods of inducing an immunomodulatory tumor response
CA3204204A1 (en) * 2020-12-11 2022-06-16 Materia Therapeutics Inc. Cancer treatment using bosentan in combination with a checkpoint inhibitor
WO2023020291A1 (zh) * 2021-08-16 2023-02-23 应世生物科技(南京)有限公司 In10018与pld的联用
JP2024545147A (ja) * 2021-12-10 2024-12-05 ▲應▼世生物科技（南京）有限公司 腫瘍治療の医薬組合せ及び使用
WO2023193705A1 (zh) * 2022-04-07 2023-10-12 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
EP4545080A1 (en) * 2022-06-24 2025-04-30 Inxmed (Nanjing) Co., Ltd. Pharmaceutical combination for treating tumors and use thereof
EP4578449A4 (en) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE
JP2025528528A (ja) * 2022-09-05 2025-08-28 ▲應▼世生物科技（南京）有限公司 Ｆａｋ阻害剤及びｅｇｆｒ－ｔｋｉの薬学的組合せ及び使用
JP2025529512A (ja) * 2022-09-16 2025-09-04 ▲應▼世生物科技（南京）有限公司 Ｆａｋ阻害剤及びトポイソメラーゼ阻害剤の医薬組合せ、並びにその使用
CN119947725A (zh) * 2022-09-30 2025-05-06 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
CN121079314A (zh) * 2023-01-24 2025-12-05 辛查 Il-18 公司 用于组合疗法的方法和组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
FI20030976A7 (fi) 2003-06-30 2004-12-31 M Real Oyj Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi
DK1761132T3 (da) 2004-06-30 2012-03-05 Cadbury Holdings Ltd Tyggegummi, som omfatter aromastofemulsion
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2681015C (en) 2007-03-16 2016-06-21 The Scripps Research Institute Inhibitors of focal adhesion kinase
AP2009005010A0 (en) 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
US20100317663A1 (en) 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
JP5551689B2 (ja) 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
CN103930114A (zh) * 2011-06-28 2014-07-16 葛兰素史密斯克莱知识产权（第2号）有限公司 给药和治疗方法
EP2903644A4 (en) * 2012-10-05 2016-03-09 Cerulean Pharma Inc TREATMENT OF CANCER
WO2015061796A1 (en) 2013-10-25 2015-04-30 Nodality Inc. Methods and compositions for immunomodulation
HUE043042T2 (hu) * 2013-11-01 2019-07-29 Pfizer Vektorok prosztatához kapcsolódó antigének expressziójára
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
WO2017201043A1 (en) 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer

Similar Documents

Publication Publication Date Title
Kim et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
JP2020090509A (ja) 非小細胞肺がんを治療するための抗ｂ７−ｈ１および抗ｃｔｌａ−４抗体
JP2018508512A5 (enExample)
JP2018518454A5 (enExample)
JP2017533912A5 (enExample)
JP2020532537A5 (enExample)
JP2025185043A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
JP2016516800A5 (enExample)
JP2022512851A5 (enExample)
CN114209841A (zh) 治疗组合物、组合和使用方法
Froesch et al. Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Jiang et al. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study.
JPWO2022270524A5 (enExample)
JP2021511344A5 (enExample)
JP2024519450A5 (enExample)
HK1225995A1 (zh) 用於治疗或缓解高龄或晚期癌症患者的药物组合物
Bironzo et al. Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?
Benitez et al. Hepatic intra-arterial chemotherapy with immunotherapy in NSCLC
TW202317183A (zh) 藉由併用ｃｄ４７抑制物質、免疫檢查點抑制物質及標準療法之癌症治療法
Alquraini Dostarlimab: Novel paradigm shift in cancer therapy.
NZ739490B2 (en) Therapeutic compositions, combinations, and methods of use
TW201922292A (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
JPWO2022270523A5 (enExample)
EP4637731A1 (en) Combination therapy for treating cancer
CN117460534A (zh) 基于cd47抑制物质、免疫检查点抑制物质和标准疗法的联用的癌症治疗方法